Advertisement

Misonidazole and Desmethylmisonidazole in Clinical Radiotherapy

  • S. Dische
Part of the NATO Advanced Study Institutes Series book series (NSSA, volume 43)

Abstract

The first administration of misonidazole to a patient receiving radiotherapy was performed at Mount Vernon on the 1st November 1974. In the first phase of the work, when large single doses were given to 8 patients, we showed that good serum concentrations could be achieved in man with doses which were fairly well tolerated when given orally. The curve of plasma concentration showed a peak at 1 to 2 hours and then a period of slow-fall called the plateau period extending up to 4 or 5 hours. The concentration then fell away with a half-life of approximately 12 hours. Enhancement of radiation response in skin made artificially hypoxic was demonstrated in all 6 cases studied and concentrations up to 100% of the plasma concentration were found in biopsies of human tumours. An enhancement of tumour response was observed in 3 of 4 patients with multiple deposits of tumour where a comparison could be made of treatment with or without the drug (1,2,3).

Keywords

Hyperbaric Oxygen Hypoxic Cell Hypoxic Tumour Cell Tumour Concentration Plateau Concentration 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    S. Dische, A. J. Gray and G. D. Zanelli, Clinical testing of the radiosensitizer Ro 07–0582. II. Radiosensitization of normal and hypoxic skin, Clin. Radiol. 27:159 (1976).PubMedCrossRefGoogle Scholar
  2. 2.
    A. J. Gray, S. Dische, G. E. Adams, I. R. Flockhart, and J. L. Foster, Clinical testing of the radiosensitizer Ro 07–0582. I. Dose tolerance, serum and tumour concentration, Clin. Radiol. 27:151 (1976).PubMedCrossRefGoogle Scholar
  3. 3.
    R. H. Thomlinson, S. Dische, A. J. Gray, and L. M. Errington, Clinical testing of the radiosensitizer Ro 07–0582. III. Regression and regrowth of tumour, Clin. Radiol. 27:167 (1976).PubMedCrossRefGoogle Scholar
  4. 4.
    S. Dische, M. I. Saunders, M. E. Lee, G. E. Adams, and I. R. Flockhart, Clinical testing of the radiosensitizer Ro 07–0582: Experience with multiple doses, Br. J. Cancer 35:567 (1977).PubMedCrossRefGoogle Scholar
  5. 5.
    M. I. Saunders, S. Dische, P. Anderson, and I. R. Flockhart, The neurotoxicity of misonidazole and its relationship to dose, half-life and concentration in the serum, Br. J. Cancer 37(Suppl.III):268 (1978).Google Scholar
  6. 6.
    S. Dische, M. I. Saunders, I. R. Flockhart, M. E. Lee and P. Anderson, Misonidazole. A drug for trial in radiotherapy and oncology, Int. J. Radiat. Oncol. Biol. Phys. 5:851 (1979).PubMedCrossRefGoogle Scholar
  7. 7.
    S. Dische, M. I. Saunders, and I. R. Flockhart, The optimum regime for the administration of misonidazole and the establishment of multi-centre clinical trials, Br. J. Cancer 37(Suppl.III):318 (1978).Google Scholar
  8. 8.
    J. Denekamp, F. J. Fowler and M. C. Joiner, Misonidazole in fractionated radiotherapy: little and often? Br. J. Radiol. (Awaiting publication).Google Scholar
  9. 9.
    R. Sealy and W. Levin, Clinical experience with misonidazole as a radiation sensitizer and as a radiation sensitizer in conjunction with hyperbaric oxygen or hyperthermia, Cancer Clin. Trials (1980)(Awaiting publication).Google Scholar
  10. 10.
    N. M. Bleehen, The Cambridge glioma trial misonidazole and radiation therapy with associated pharmacokinetic studies, Cancer Clin. Trials (1980)(Awaiting publication).Google Scholar
  11. 11.
    H. D. Kögelnik, Clinical experience with misonidazole. High dose fractions versus daily low doses, Cancer Clin. Trials 3:179 (1980).PubMedGoogle Scholar
  12. 12.
    T. H. Wasserman and T. L. Phillips, Clinical trials of misonidazole in the United States, Cancer Clin. Trials (1980) (Awaiting publication).Google Scholar
  13. 13.
    J. P. Bataini, Personal communication (1980).Google Scholar
  14. 14.
    S. Dische, Hyperbaric oxygen. The Medical Research Council trials and their clinical significance, Br. J. Radiol. 51:888 (1978).PubMedCrossRefGoogle Scholar
  15. 15.
    T. A. Rich, S. Dische, M. I. Saunders, M. Stratford and A. Minchinton, The influence of necrosis on the concentration of misonidazole in human tumors, Int. J. Radiat. Oncol. Biol. Phys. (Awaiting publication).Google Scholar
  16. 16.
    S. Dische, M. I. Saunders, P. Anderson, M. E. Lee, J. F. Fowler, M. Stratford and A. Minchinton, A drug for improved radio-sensitization in radiotherapy, Br. J. Cancer (1980) (Awaiting publication).Google Scholar
  17. 17.
    D. V. Ash, M. R. Smith and R. D. Bugden, The distribution of misonidazole in human tumours and normal tissue, Br. J. Cancer 39:503 (1979).PubMedCrossRefGoogle Scholar
  18. 18.
    S. Dische, M. I. Saunders, P. J. Riley, J. Hauck, M. H. Bennett, M. R. L. Stratford and A. I. Minchinton, The concentration of desmethylmisonidazole in human tumours and in cerebrospinal fluid, Br. J. Cancer (1980) (Submitted for publication).Google Scholar

Copyright information

© Plenum Press, New York 1982

Authors and Affiliations

  • S. Dische
    • 1
  1. 1.Marie Curie Research Wing for Oncology, Regional Radiotherapy CentreMount Vernon HospitalNorthwood, MiddlesexEngland

Personalised recommendations